New combo attack on tough GI cancers
NCT ID NCT07243938
Summary
This study is testing whether adding two new drugs (zanidatamab and tislelizumab) to standard chemotherapy or radiation works better for people with HER2-positive stomach or colorectal cancers. It will involve about 70 adults with specific types of advanced or spreading cancer. The main goal is to see if this combination can shrink tumors effectively and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.